ENTPD1 and cancer: In other cancer types, metformin has been demonstrated to decrease the expression of immune checkpoint components such as PD-L1 [19], CD39 and CD73 [20] both in cancer and immunosuppressive cell populations, enabling a CD8 T cell cytotoxic response [19,21].